Document is current
Any future updates will be listed below
-
Authors
Labouesse, Marie A. https://orcid.org/0000-0002-6850-5852
Torres-Herraez, Arturo
Chohan, Muhammad O. https://orcid.org/0000-0002-9359-3700
Villarin, Joseph M.
Greenwald, Julia https://orcid.org/0000-0003-3915-6187
Sun, Xiaoxiao
Zahran, Mysarah
Tang, Alice
Lam, Sherry
Veenstra-VanderWeele, Jeremy
Lacefield, Clay O. https://orcid.org/0000-0001-5721-434X
Bonaventura, Jordi https://orcid.org/0000-0002-4745-0151
Michaelides, Michael https://orcid.org/0000-0003-0398-4917
Chan, C. Savio https://orcid.org/0000-0002-3474-1718
Yizhar, Ofer https://orcid.org/0000-0003-4228-1448
Kellendonk, Christoph https://orcid.org/0000-0003-3302-2188
- License Information
-
More Information
Article History
Received: 28 January 2023
Accepted: 5 October 2023
First Online: 23 October 2023
Competing interests
: J.B. and M.M. (individuals) are listed as inventors on an application (62/627,527) filed with the U.S. Patent Office regarding DREADD compounds, but none of these compounds are used in the manuscript. M.M. has received research funding from AstraZeneca, Redpin Therapeutics, and Attune Neurosciences. J.V.-V. has served on advisory boards for Roche, Novartis, and SynapDx; has received research funding from Roche, Novartis, SynapDx, Forest, Janssen, Yamo, MapLight, and Seaside Therapeutics; and has received editorial stipends from Wiley and Springer. O.Y. (indiviual) is listed as an inventor on a patent application (US20210403518A1) filed with the US Patent Office regarding the optogenetic tool eOPN3 used in Fig. and Fig. S, and serves as a consultant for Modulight.bio. Remaining authors declare no competing interests.
